Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BHARAT PARENTERALS LTD.

NSE : NABSE : 541096ISIN CODE : INE365Y01019Industry : Pharmaceuticals & DrugsHouse : Private

BSE1685.00-11.8 (-0.7 %)

PREV CLOSE ( ) 1696.80

OPEN PRICE ( ) 1697.05

BID PRICE (QTY) 1681.00 (1)

OFFER PRICE (QTY) 1685.00 (17)

VOLUME 1003

TODAY'S LOW / HIGH ( )1685.00 1738.95

52 WK LOW / HIGH ( ) 321.21824.7

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992

Management Info

- Chairman Bharat Desai - Managing Director

Registered Office

Address Survey No. 144 A,Jarod - Samlaya Road,Haripura, Savli,
Vadodara,
Gujarat-391520

Phone 02667 - 251670, 251680, 9909928332

Email info@bplindia.in / cs@bplindia.in

Website www.bplindia.in

Registrars Details

Adroit Corporate Services Pvt Ltd

18-20, 1st floor, Plot No 639,Makwana Road,,Marol, Andheri (East),Mumbai

Listing : BSE

NEWS

29Apr Allotment of Equity Shares
Preferential Issue of shares Inter-alia, considered and approved the fo..

22Mar Bharat Parenterals informs about detai
Pursuant to Regulation 39(3) of the SEBI Listing Obligations and Disclos..

13Mar Bharat Parenterals’ arm signs deal wit
Bharat Parenterals’ subsidiary Innoxel Lifesciences has signed a deal to..

02Mar Bharat Parenterals informs about analy
Pursuant to Regulation 30 of the Listing Regulations read with clause 15..

03Feb Bharat Parenterals informs about loss
Pursuant to Regulation 39(3) of the SEBI Listing Obligations and Disclos..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	50.7	243.4
Gross Profit	69	321.7
Operating Profit	91.8	402.1
Net Sales	588	2179.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE) 2428.60 (8.75%)	M.Cap ( in Cr)30597.50
Torrent Pharma (BSE) 2767.00 (3.49%)	M.Cap ( in Cr)93035.27
Abbott India (BSE) 26690.65 (0.32%)	M.Cap ( in Cr)56655.85
Dr. Reddy's Lab (BSE) 6322.80 (0.55%)	M.Cap ( in Cr)105255.65
Glaxosmithkline Phar (BSE) 2137.90 (1.63%)	M.Cap ( in Cr)35861.56

Shareholding Pattern

	PROMOTERS	73.27%
	NON-INSTITUTION	26.73%
	FI/BANKS/INSURANCE	0.01%
	MUTUAL FUNDS/UTI	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

BHARAT PARENTERALS LTD.